GleamWall
中文EN

PVLA PALVELLA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1583648 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-113.9%
TTM EPS YoY-120.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-63.4%
ROA-49.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.3%
Debt / equity0.00x
Current ratio16.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-20.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$22.84M$8.15M
SG&A expense$15.76M$5.94M
Operating income-$38.60M-$14.10M
Interest expense$0$430,000
Pretax income-$41.72M-$17.43M
Income tax$0$0
Net income-$41.72M-$17.43M
EPS (basic)-3.71-7.83
EPS (diluted)-3.71-7.83
Weighted avg. shares (diluted)11.25M2.23M
Banking
Net interest income$2.59M$642,000
Balance sheet
Cash & equivalents$57.98M$83.60M
Short-term investments$0—
Receivables$0$358,000
Current assets$58.99M$88.23M
Total assets$59.56M$88.23M
Current liabilities$11.34M$12.04M
Total liabilities$31.58M$25.63M
Shareholders' equity$27.98M$62.61M
Shares outstanding12.38M11.01M
Cash flow statement
Operating cash flow-$25.01M-$10.84M
Financing cash flow-$660,000$87.09M
Stock-based compensation$6.40M$830,000

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.